Janus Kinase Inhibitor

In rheumatology, the next generation of new therapies always seems to be just out of reach, or perpetually “only a few years” away. However, several novel, and not-so-novel, approaches are giving hope that the future may finally soon arrive.

Incretin-based therapies, which were developed for the treatment of diabetes and obesity because of their ability to target defects that are not addressed by other medications, are continuing to evolve.

A Janus kinase inhibitor may preserve beta-cell function for children and young adults recently diagnosed with type 1 diabetes, according to findings published in The New England Journal of Medicine.

SAN DIEGO — Kathryn Dao, MD, discusses a study presented at ACR Convergence 2023 that compared the initiation of TNF inhibitors with non-TNF inhibitor biologics or JAK inhibitors among patients with rheumatoid arthritis-associated interstitial lung disease.

Treatment with Janus kinase inhibitors may be associated with elevated odds of acne, especially among those with dermatologic conditions, according to a study.

Opzelura achieved significant efficacy for the treatment of atopic dermatitis in children aged as young as 2 years, Incyte announced in a press release.

SAN DIEGO — Patient age and disease-related factors may be driving safety signals in medications used to treat rheumatoid arthritis and psoriatic disease, according to a speaker at the 2023 Congress of Clinical Rheumatology West.

SAN DIEGO — Rheumatology research still offers too few head-to-head clinical trials of biologic medications to help clinicians manage rheumatoid arthritis, according to data presented at the 2023 Congress of Clinical Rheumatology West.